Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Arsenic trioxide was studied in a Phase 2 trial for relapsed or refractory chronic myeloid leukemia, and the trial has completed. The document provides a clinic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Trisenox (arsenic trioxide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED